51. Radioterapija raka glave in vratuGaber Plavc, 2022, published professional conference contribution Abstract: Radioterapija je eden treh stebrov zdravljenja rakov glave in vratu. Začetki segajo v konec 19. stoletja, vsa dosedanja spoznanja pa danes omogočajo uspešno zdravljenje ob sprejemljivi toksičnosti. S sodobnimi obsevalnimi tehnikami lahko pri sluzničnih karcinomih glave in vratu v zgodnjih stadijih dosežemo popolno lokalno kontrolo bolezni, medtem ko je pri lokoregionalni bolezni obsevanje pogosto edino zdravljenje, ki prinaša možnost ozdravitve. V prihodnosti lahko ob tehničnem napredku, kot sta uporaba adaptivnega pristopa k obsevanju in uporaba visokoenergijskih delcev z ugodnejšimi fizikalnimi lastnostmi, ter predvsem ob napredku v razumevanju mehanizmov občutljivosti na obsevanje pričakujemo nadaljnje pomembne korake k izboljšanju uspehov radioterapije ob nespremenjeni ali celo zmanjšani toksičnosti. Keywords: rak glave in vratu, radioterapija, onkološko zdravljenje Published in DiRROS: 06.01.2023; Views: 429; Downloads: 94 Full text (534,94 KB) |
52. |
53. Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccinationUrška Janžič, Urška Bidovec, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čakš, Erik Škof, Jerneja Debeljak, Peter Korošec, Matija Rijavec, 2022, original scientific article Abstract: Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted. Keywords: onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer Published in DiRROS: 24.06.2022; Views: 772; Downloads: 318 Full text (2,03 MB) |
54. Minimalno invazivni diagnostični pristopi pri primarnih možganskih tumorjih z uporabo prosto cirkulirajočih nukleinskih kislinMarija Skoblar Vidmar, Jernej Mlakar, Uroš Smrdel, Alenka Matjašič, Jože Pižem, Andrej Zupan, 2021, published scientific conference contribution Keywords: tekočinska biopsija, onkološko zdravljenje, možganski tumorji Published in DiRROS: 04.04.2022; Views: 569; Downloads: 219 Full text (123,97 KB) |
55. |
56. |
57. |
58. |
59. |
60. |